At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 310 enrolled
Drug / intervention
Interferon Alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).
Gruppo Oncologico Italiano di Ricerca Clinica·interventional·Posted Jul 17, 2007·Updated Jul 10, 2013
In Brief
A Phase 3 clinical trial evaluating Interferon Alfa-2a and Interleukin-2 for Carcinoma, Renal Cell. Completed, enrolled 310 participants across 8 sites.
Detailed Summary
The aim of this study is to compare the efficacy (in terms of event-free survival and overall survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see program in patient with radically operated renal cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesItaly
Collaborators--
Timeline
Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 1994
Primary CompletionApr 2007
First PostedJul 2007
Study CompletionJun 2012
TodayJul 2026
First PostedJul 17, 2007
Enrollment StartJul 1, 1994
Primary CompletionApr 1, 2007
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 12.8 yearsPosted 19.0 years ago
Interventions
Interferon Alfa-2adrug
Interferon Alfa-2a in combination with Interleukin
Interleukin-2drug
Interferon Alfa-2a in combination with Interleukin